Enteric-coated Mycophenolate Sodium as a Corticosteroid-sparing Agent for the Treatment of Autoimmune Scleritis

Purpose: To evaluate enteric-coated mycophenolate sodium (EC-MPS) as a corticosteroid-sparing agent in the treatment of autoimmune scleritis. Methods: A retrospective, interventional, noncomparative review of EC-MPS use in patients with autoimmune scleritis. Results: Seven eyes of 5 patients (all female; median age: 47 years, range: 20-55 years) with inflammatory scleral disease were treated with EC-MPS. The mean follow-up duration was 16.4 months (range, 12-20 months). EC-MPS was started at 360 mg twice daily. The mean time to treatment success was 1.6 months (range, 1-3 months). The mean prednisolone dosage at the onset of EC-MPS was 24 mg daily (range, 15-30 mg), and this was reduced to 6.5 mg daily (range, 0-10 mg) as inflammation control was achieved. No severe adverse events except for 1 patient with transient knee pain were reported; the incidence of adverse events after using EC-MPS was 1/6.83 person-years. There was no recurrence of scleral inflammation during the follow-up period. Conclusions: EC-MPS can be used as a corticosteroid-sparing agent to safely suppress inflammatory autoimmune scleritis.

[1]  S. Bhandari,et al.  Effect of conversion from mycophenolate mofetil to enteric‐coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[2]  P. Bhat,et al.  Mycophenolate Mofetil Therapy for Sarcoidosis-Associated Uveitis , 2009, Ocular immunology and inflammation.

[3]  P. L. Daele,et al.  Mycophenolate Sodium: Effective Treatment for Therapy-Refractory Intestinal Behçet's Disease, Evaluated With Enteroscopy , 2008, The American Journal of Gastroenterology.

[4]  M. Lam,et al.  Cost Comparison Between Mycophenolate Mofetil and Cyclophosphamide-Azathioprine in the Treatment of Lupus Nephritis , 2008, The Journal of Rheumatology.

[5]  W. Hop,et al.  Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome , 2008, Pediatric Nephrology.

[6]  D. Jabs,et al.  Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. , 2008, Ophthalmology.

[7]  R. Vijayaraghavan,et al.  Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. , 2008, Transplantation proceedings.

[8]  J. Ehrich,et al.  Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric‐coated mycophenolate sodium in kidney transplanted children , 2008, Pediatric transplantation.

[9]  M. Rela,et al.  Long‐term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  L. Sobrin,et al.  Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. , 2008, Ophthalmology.

[11]  M. Zierhut,et al.  Mycophenolate Sodium for Immunosuppressive Treatment in Uveitis , 2008, Ocular immunology and inflammation.

[12]  S. Mulgaonkar,et al.  Patient-Reported Gastrointestinal Symptom Burden and Health-Related Quality of Life following Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium , 2006, Transplantation.

[13]  E. Hernández,et al.  Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. , 2005, Transplantation proceedings.

[14]  M. Salvadori.  LONG TERM ADMINISTRATION OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS, MYFORTIC) IS SAFE IN KIDNEY TRANSPLANT PATIENTS. , 2004, Clinical nephrology.

[15]  K. Budde,et al.  Review of the immunosuppressant enteric-coated mycophenolate sodium , 2004, Expert opinion on pharmacotherapy.

[16]  H. Sollinger.  Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. , 2004, Transplantation proceedings.

[17]  Jeff Maca,et al.  Enteric‐Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novo Renal Transplant Patients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  R. Nussenblatt,et al.  Mycophenolate mofetil for the treatment of scleritis. , 2003, Ophthalmology.

[19]  D. Jabs,et al.  Episcleritis and scleritis: clinical features and treatment results. , 2000, American journal of ophthalmology.

[20]  S. Lightman,et al.  Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. , 1999, Ophthalmology.

[21]  A. Allison,et al.  Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. , 1990, Transplantation proceedings.

[22]  C. Foster,et al.  Scleritis in relapsing polychondritis. Response to therapy. , 1990, Ophthalmology.

[23]  Wolters Kluwer,et al.  Enteric-Coated Mycophenolate Sodium A Review of its Use in the Prevention of Renal Transplant Rejection , 2008 .